Shots:

• The companies plan to leverage TenNor’s multitargeting drug conjugation platform to discover new therapies for NTM diseases. The agreement was facilitated by J&J
• The focus of the pact to discover and develop novel therapies for NTM diseases with the potential to shorten the duration of treatment with better safety and efficacy
• The collaboration builds on the scientific know-how and background IP of TenNor associated with its drug conjugation technology. The collaboration will integrate companies’ expertise together to discover new treatment modalities for NTM diseases

 ­ Ref: PRNewswire | Image: Janssen